Neurogene Quarterly Balance Sheet
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurogene financial position
As of Jun 30, 2026, Neurogene reported total assets of $244.4 million, down 17.8% from a year earlier against total liabilities of $27.2 million. Shareholders' equity stood at $217.1 million, or 88.9% of assets. The company held $112.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.64, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Neurogene balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 112.48M | 124.16M | 103.84M | 71.00M | 58.81M | 70.77M | 136.59M | 66.63M | 111.03M | 150.14M | 148.21M | 25.23M |
| Short-Term Investments | 112.91M | 119.02M | 165.17M | 194.41M | 215.71M | 221.83M | 175.82M | 72.36M | 42.87M | 19.39M | 48.95M | 53.28M |
| Total Current Assets | 228.91M | 246.75M | 271.77M | 270.52M | 278.99M | 296.40M | 315.92M | 143.65M | 159.15M | 174.14M | 200.35M | 79.89M |
| Property, Plant & Equipment | 11.73M | 12.50M | 12.79M | 13.48M | 14.25M | 14.81M | 15.42M | 16.07M | 16.06M | 16.48M | 17.17M | 484.00K |
| Total Assets | 244.36M | 263.14M | 288.60M | 287.83M | 297.32M | 315.30M | 335.73M | 164.12M | 179.82M | 195.35M | 222.57M | 89.59M |
| Accounts Payable | 3.29M | 4.68M | 1.95M | 1.54M | 2.06M | 3.06M | 1.34M | 1.68M | 1.72M | 1.52M | 2.60M | 3.66M |
| Total Current Liabilities | 21.50M | 18.87M | 16.41M | 14.71M | 15.44M | 14.09M | 15.16M | 15.80M | 13.07M | 11.82M | 22.97M | 5.21M |
| Total Liabilities | 27.23M | 25.36M | 23.72M | 22.29M | 24.06M | 23.51M | 25.36M | 26.71M | 24.81M | 24.57M | 36.55M | 14.35M |
| Shareholders' Equity | 217.13M | 237.78M | 264.89M | 265.54M | 273.25M | 291.80M | 310.38M | 137.41M | 155.01M | 170.78M | 186.02M | -183.21M |
| Retained Earnings | -418.07M | -383.58M | -352.65M | -327.91M | -306.96M | -284.94M | -262.30M | -242.78M | -222.57M | -204.07M | -187.15M | -471.87M |
| Net Cash (Debt) | 225.39M | 243.18M | 269.01M | 265.41M | 274.52M | 292.60M | 312.40M | 138.99M | 153.91M | 169.53M | 197.16M | 78.51M |
| Shares Outstanding | 15.83M | 15.62M | 15.49M | 14.78M | 14.27M | 14.93M | 14.85M | 13.01M | 12.99M | 12.86M | 12.82M | 8.81M |
This table shows 12 quarterly periods of Neurogene's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow NGNE's reporting calendar. What is a balance sheet?